Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation

Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma

(2016) Philippe Moreau et al.   LEUKEMIA & LYMPHOMA

The novel biomarker of alternative macrophage activation, soluble mannose receptor (sMR/sCD206): Implications in multiple myeloma

(2015) Morten N. Andersen et al.   LEUKEMIA RESEARCH

Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway

(2015) Cuixia Yang et al.   MEDICAL ONCOLOGY

Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth

(2015) G. Gritsina et al.   MOLECULAR CANCER THERAPEUTICS

Chemokines CCL2, 3, 14 stimulate macrophage bone marrow homing, proliferation, and polarization in multiple myeloma

(2015) Yi Li et al.   Oncotarget

Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells

(2015) Kim De Veirman et al.   Oncotarget

Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma

(2015) Arianna Calcinotto et al.   OncoImmunology

Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo

(2015) Shuang Yan et al.   Oncotarget

Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype

(2015) Katia Beider et al.   Oncotarget

AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells

(2015) Sarah K. Maenhout et al.   Oncotarget

Monocyte/macrophage-derived soluble CD163: a novel biomarker in multiple myeloma

(2014) Morten N. Andersen et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines

(2014) Peter J. Murray et al.   IMMUNITY

Tumor-associated macrophages as a prognostic parameter in multiple myeloma

(2013) Elif Suyanı et al.   ANNALS OF HEMATOLOGY

Tumor Hypoxia Does Not Drive Differentiation of Tumor-Associated Macrophages but Rather Fine-Tunes the M2-like Macrophage Population

(2013) D. Laoui et al.   CANCER RESEARCH

The Janus Kinases Inhibitor AZD1480 Attenuates Growth of Small Cell Lung Cancers In Vitro and In Vivo

(2013) J.-H. Lee et al.   CLINICAL CANCER RESEARCH

Downregulation of Stat3 in melanoma: reprogramming the immune microenvironment as an anticancer therapeutic strategy

(2013) P U Emeagi et al.   GENE THERAPY

Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells

(2012) Jaehyup Kim et al.   BRITISH JOURNAL OF HAEMATOLOGY

PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma

(2012) Y Zheng et al.   LEUKEMIA

Different Tumor Microenvironments Contain Functionally Distinct Subsets of Macrophages Derived from Ly6C(high) Monocytes

(2010) K. Movahedi et al.   CANCER RESEARCH

Macrophage Diversity Enhances Tumor Progression and Metastasis

(2010) Bin-Zhi Qian et al.   CELL

The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival

(2010) A Scuto et al.   LEUKEMIA

Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis

(2009) Y. Zheng et al.   BLOOD

 1 Integrin Adhesion Enhances IL-6-Mediated STAT3 Signaling in Myeloma Cells: Implications for Microenvironment Influence on Tumor Survival and Proliferation

(2009) K. H. Shain et al.   CANCER RESEARCH

Multiple myeloma

(2009) Marc S Raab et al.   LANCET

Environmental-mediated drug resistance: a target for multiple myeloma therapy

(2009) Kenneth H Shain et al.   Expert Review of Hematology